Share on StockTwits

Cross Country Healthcare (NASDAQ:CCRN) Director Emil Hensel sold 3,000 shares of the company’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $6.75, for a total value of $20,250.00. Following the completion of the sale, the director now directly owns 100,608 shares of the company’s stock, valued at approximately $679,104. The transaction was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Cross Country Healthcare from a “neutral” rating to an “underperform” rating in a research note on Monday, May 12th. They now have a $5.40 price target on the stock.

Shares of Cross Country Healthcare (NASDAQ:CCRN) traded up 0.15% during mid-day trading on Friday, hitting $6.75. 386,550 shares of the company’s stock traded hands. Cross Country Healthcare has a 52-week low of $4.83 and a 52-week high of $11.54. The stock has a 50-day moving average of $6.27 and a 200-day moving average of $8.3. The company’s market cap is $210.0 million.

Cross Country Healthcare (NASDAQ:CCRN) last released its earnings data on Wednesday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.02. The company had revenue of $118.10 million for the quarter, compared to the consensus estimate of $120.21 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. Analysts expect that Cross Country Healthcare will post $0.05 EPS for the current fiscal year.

Cross Country Healthcare, Inc (NASDAQ:CCRN) is engaged in the healthcare staffing services business offering a suite staffing and outsourcing services to the healthcare market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.